MyFinsight
Home
Blog
About
Contact
Download
Download image
Other current assets
$1,123,300K
Inventory
$2,168,100K
Due from anti-cd20
therapeutic programs
$524,600K
Accounts receivable, net
of allowance for...
$1,342,400K
Current portion of
marketable securities
$807,200K
Cash and cash
equivalents
$3,008,500K
Investments and other assets
$750,600K
Deferred tax asset
$292,500K
Goodwill
$6,491,100K
Intangible assets, net
$9,178,500K
Operating lease assets
$265,400K
Property, plant and
equipment, net
$3,055,400K
Marketable securities
$431,900K
Total current assets
$8,974,100K
Total assets
$29,439,500K
Total liabilities and
equity
$29,439,500K
Total equity
$18,256,800K
Total liabilities
$11,182,700K
Treasury stock, at cost
23.8 million and 23.8...
$2,977,100K
Accumulated other
comprehensive income (loss)
-$182,000K
Retained earnings
$20,552,700K
Other long-term
liabilities
$748,500K
Long-term operating lease
liabilities
$290,400K
Deferred tax liability
$507,600K
Notes payable
$6,286,800K
Total current
liabilities
$3,349,400K
Additional paid-in capital
$863,100K
Common stock, par value
0.0005 per share
$100K
Accrued expense and
other
$2,802,600K
Accounts payable
$432,000K
Taxes payable
$114,800K
Back
Back
Balance Sheet
source: myfinsight.com
Biogen-svg
BIOGEN INC. (BIIB)
Biogen-svg
BIOGEN INC. (BIIB)